Oleclumab
- Generic Name
- Oleclumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1803176-05-7
- Unique Ingredient Identifier
- 5CRY01URYQ
- Background
Oleclumab is under investigation in clinical trial NCT03819465 (A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC).
- Associated Conditions
- -
- Associated Therapies
- -
Novel Perioperative Combinations Show Efficacy in Resectable NSCLC
NeoCOAST-2 trial showed high pathologic complete response (pCR) and major pathologic response (mPR) rates in resectable NSCLC patients treated with novel combinations, with Dato-DXd plus durvalumab and single-agent platinum chemotherapy achieving the highest pCR (34.1%) and mPR (65.9%) rates. All arms demonstrated manageable safety profiles and comparable surgical rates.
Related Clinical Trials:
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath